ICER’s Unsupported Price Increase Assessment

In October 2019, the Institute of Clinical and Economic Review (ICER) released their first annual report on Unsupported Price Increases of prescription drugs in the United States. The report takes a systematic approach to determine whether certain price increases are justified by new clinical evidence or other factors. Our Health Strategies Insights team conducted a survey with twenty medical directors and pharmacy directors from leading health plans to gather reactions on the recently published Unsupported Price Increase Assessment, and understand ICER’s impact on coverage determinations.

Learn more about our  HTANAVIGATOR by EVERSANA™!

Fill out the form below to download the ICER’s Unsupported Price Increase Assessment.

Author
Heather Lee Whipple
Senior Vice President, Health Strategies

Heather Lee is responsible for leading and expanding the brand market access insights capabilities within Health Strategies Insights, the comprehensive market access research and insights portfolio, in order to help life science innovators make more informed decisions throughout the product lifecycle. With more than 20 years of experience leading market access strategy and innovation, Heather […]